- Assembly Biosciences Inc Extraordinary Shareholders Meeting TranscriptJan 31, 2024
- Assembly Biosciences Inc Partnership with Gilead Sciences Inc to Develop Next-Generation Antiviral Therapeutics Call TranscriptOct 17, 2023
- Assembly Biosciences Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 25, 2023
- Assembly Biosciences Inc HSV-2 and Transplant-Associated Herpesviruses Research - Corporate Call TranscriptAug 31, 2022
- Assembly Biosciences Inc IFNAR (Interferon-a Receptor Agonist) Research - Corporate Call TranscriptJul 26, 2022
- Assembly Biosciences Inc HBV/HDV Entry Inhibitor Research - Corporate Call TranscriptMar 31, 2022
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptMay 20, 2021
- Assembly Biosciences Inc Earnings Call TranscriptFeb 25, 2021$66.36 (-1.95%)Earnings
- Assembly Biosciences, Inc. - Special Call TranscriptNov 05, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptJul 20, 2020
- Assembly Biosciences Inc Annual Shareholders Meeting TranscriptJun 11, 2020
- Assembly Biosciences Inc to Discuss HBV Portfolio Progress Call TranscriptMay 07, 2020
- Assembly Biosciences, Inc. - Special Call TranscriptNov 11, 2019
- Assembly Biosciences, Inc Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 Call TranscriptApr 15, 2019
Assembly Biosciences, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Assembly Biosciences AASLD 2019 Review Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand your conference over to your speaker today, Lauren Glaser, Senior Vice President, Investor Relations. Please go ahead, ma'am.
Good morning, and thank you for joining us as we discuss today our company's 2 presentations at The Liver Meeting, the 2019 Annual Meeting of the American Association for the Study of Liver Diseases currently being held in Boston. We are pleased to share the encouraging new data for 731 and 2158, our 2 lead HBV core inhibitor candidates featured today in 2 late-breaking poster presentations.
In a moment, I will turn the call over to Dr. John McHutchison, Assembly's CEO and President, to set the stage with some introductory remarks. And then Dr. Richard Colonno, EVP and Chief Scientific
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)